Andrew Simmons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Simmons has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Steve Charles Rees Williams
Department of Neuroimaging Institute of Psychiatry, Psychology and Neuroscience King's College London London UK
2 shared publications Alan Evans
Montreal Neurological Institute, McGill University, Montréal, Canada
1 shared publicationAstrid Pauls
1 shared publicationBiba R. Stanton
King's College London, MRC Centre for Neurodegeneration Research, Institute of Psychiatry, Department of Clinical Neuroscience, London
1 shared publicationBruno Vellas
Toulouse Gerontopole University Hospital, Univeriste Paul Sabatier, INSERM U 558, France
1 shared publicationCamilla R. V. Blain
King's College London, MRC Centre for Neurodegeneration Research, Institute of Psychiatry, Department of Clinical Neuroscience, UK
1 shared publication
Latest Publications
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S108
Poster #S54 BRAIN STRUCTURAL ABNORMALITIES IN POSTPARTUM PSYCHOSIS: AN MRI STUDY
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S108
Poster #S54 BRAIN STRUCTURAL ABNORMALITIES IN POSTPARTUM PSYCHOSIS: AN MRI STUDY
- 14 December 2010
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 26 (1) , 75-82
The AddNeuroMed framework for multi‐centre MRI assessment of Alzheimer's disease : experience from the first 24 months
Objective: To describe the AddNeuroMed imaging framework for multi‐centre magnetic resonance imaging (MRI) assessment of longitudinal changes in Alzheimer's disease and report on early results from the first 24 months of the project.Methods: A multi‐centre study similarly to a faux clinical trial has been established to assess longitudinal MRI changes in Alzheimer disease (AD), mild cognitive impairment (MCI) and healthy control subjects using an image acquisition protocol compatible with Alzheimer disease neuroimaging initiative (ADNI). Comprehensive quality control (QC) measures have been established throughout the study. An intelligent web‐accessible database holds details on both the raw images and data processed using a sophisticated image analysis pipeline.Results: A total of 378 subjects have been recruited (130 AD, 131 MCI, 117 healthy controls) of which a high percentage (97.3%) of the T1‐weighted volumes passed the QC criteria. Measurements of normalized whole brain volume and whole brain cortical thickness showed significant differences between AD and controls, AD and MCI and MCI and controls.Conclusions: A framework for multi‐centre MRI studies of Alzheimer's disease has been established consisting of a harmonized MRI acquisition protocol across centres, rigorous QC at both the sites and central data analysis hub and an automated image analysis pipeline. Early results demonstrate the high quality of the images acquired and the applicability of the automated image analysis techniques employed. Copyright © 2010 John Wiley & Sons, Ltd.
- 14 December 2010
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 26 (1) , 75-82
The AddNeuroMed framework for multi‐centre MRI assessment of Alzheimer's disease : experience from the first 24 months
Objective: To describe the AddNeuroMed imaging framework for multi‐centre magnetic resonance imaging (MRI) assessment of longitudinal changes in Alzheimer's disease and report on early results from the first 24 months of the project.Methods: A multi‐centre study similarly to a faux clinical trial has been established to assess longitudinal MRI changes in Alzheimer disease (AD), mild cognitive impairment (MCI) and healthy control subjects using an image acquisition protocol compatible with Alzheimer disease neuroimaging initiative (ADNI). Comprehensive quality control (QC) measures have been established throughout the study. An intelligent web‐accessible database holds details on both the raw images and data processed using a sophisticated image analysis pipeline.Results: A total of 378 subjects have been recruited (130 AD, 131 MCI, 117 healthy controls) of which a high percentage (97.3%) of the T1‐weighted volumes passed the QC criteria. Measurements of normalized whole brain volume and whole brain cortical thickness showed significant differences between AD and controls, AD and MCI and MCI and controls.Conclusions: A framework for multi‐centre MRI studies of Alzheimer's disease has been established consisting of a harmonized MRI acquisition protocol across centres, rigorous QC at both the sites and central data analysis hub and an automated image analysis pipeline. Early results demonstrate the high quality of the images acquired and the applicability of the automated image analysis techniques employed. Copyright © 2010 John Wiley & Sons, Ltd.
- 1 January 2007
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 8 (6) , 348-355
A longitudinal study of diffusion tensor MRI in ALS
In this study, we investigated whether diffusion tensor MRI (DTI) could detect progressive corticospinal tract degeneration in amyotrophic lateral sclerosis (ALS) and whether changes in diffusion variables reflected clinical deterioration. Twenty‐three ALS patients and 25 healthy volunteers underwent whole brain DTI. Patients and a subset (n = 12) of controls returned for a second scan. Clinical measures of disease severity were assessed in the ALS group. Changes in fractional anisotropy (FA) and mean diffusivity (MD) were measured along the corticospinal tract using a region of interest approach. Adequate DTI data were available in 11 ALS patients and 11 controls at two time points. FA and MD differed significantly between ALS patients and controls at both time points, but neither changed significantly over time, while global measures of disease severity in patients increased with time. Although we confirmed that DTI detects corticospinal tract damage in ALS, there were no significant changes in diffusion measures over time. The sensitivity of DTI may be improved by advanced data analysis techniques, although the high dropout rate suggests that use of MRI as a biomarker in ALS may be restricted to earlier stages of disease.
- 1 January 2007
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis
- Vol. 8 (6) , 348-355
A longitudinal study of diffusion tensor MRI in ALS
In this study, we investigated whether diffusion tensor MRI (DTI) could detect progressive corticospinal tract degeneration in amyotrophic lateral sclerosis (ALS) and whether changes in diffusion variables reflected clinical deterioration. Twenty‐three ALS patients and 25 healthy volunteers underwent whole brain DTI. Patients and a subset (n = 12) of controls returned for a second scan. Clinical measures of disease severity were assessed in the ALS group. Changes in fractional anisotropy (FA) and mean diffusivity (MD) were measured along the corticospinal tract using a region of interest approach. Adequate DTI data were available in 11 ALS patients and 11 controls at two time points. FA and MD differed significantly between ALS patients and controls at both time points, but neither changed significantly over time, while global measures of disease severity in patients increased with time. Although we confirmed that DTI detects corticospinal tract damage in ALS, there were no significant changes in diffusion measures over time. The sensitivity of DTI may be improved by advanced data analysis techniques, although the high dropout rate suggests that use of MRI as a biomarker in ALS may be restricted to earlier stages of disease.